Skip to main content
SUNFLOWER PHARMACEUTICAL GROUP CO.,LTD logo

SUNFLOWER PHARMACEUTICAL GROUP CO.,LTD — Investor Relations & Filings

Ticker · 002737 ISIN · CNE100001WT7 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,262 across all filing types
Latest filing 2025-04-24 Board/Management Inform…
Country CN China
Listing Shenzhen Stock Exchange 002737

About SUNFLOWER PHARMACEUTICAL GROUP CO.,LTD

https://www.kuihuayaoye.com

Sunflower Pharmaceutical Group Co., Ltd. focuses on the research, development, manufacturing, and distribution of proprietary Chinese medicines, chemical drugs, and health supplements. The organization is particularly noted for its specialization in pediatric medicine, marketed under the "Little Sunflower" brand, which includes treatments for respiratory and digestive ailments. Its extensive product portfolio also covers gynecological health and general internal medicine. The group operates several integrated production bases and research institutes, facilitating a comprehensive approach to drug formulation and quality control. By leveraging a robust supply chain and a wide-reaching distribution network, the company provides a diverse range of over-the-counter and prescription solutions aimed at improving family health and wellness.

Recent filings

Filing Released Lang Actions
2024年度董事会工作报告
Board/Management Information Classification · 95% confidence The document is titled '2024 年度董事会工作报告' which translates to '2024 Annual Board of Directors Work Report'. It details the board's activities, strategic planning, operational updates, governance, and committee meetings throughout the year 2024. It includes comprehensive information on company performance, board composition, committee operations, and future strategic plans. The document is lengthy (over 14,000 characters) and contains substantive content about the board's work rather than just an announcement or summary. This matches the category of Board/Management Information (MANG), which covers announcements and reports related to changes or activities of the company's board of directors or senior management. It is not an annual report (10-K) or management discussion and analysis (MDA) because it focuses specifically on the board's work and governance rather than full financial performance or management commentary. Therefore, the appropriate classification is MANG with high confidence.
2025-04-24 Chinese
关于使用部分闲置自有资金进行现金管理的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement from a company about its plan to use idle funds for cash management, including details on investment purpose, amount, authorization, risk analysis, and approvals. It is a formal disclosure of a financing-related activity but does not contain financial statements or results. The document is relatively short (1894 characters) and focuses on a capital management decision rather than reporting financial performance or results. It is not an earnings release, annual or interim report, or audit report. It is not a regulatory certification or voting result. The content fits best under Capital/Financing Update (CAP) as it informs about the company's financing activity involving cash management of idle funds.
2025-04-24 Chinese
2024年年度报告
Annual Report Classification · 100% confidence The document is titled as the "2024 年年度报告全文" which translates to "2024 Annual Report Full Text" for 葵花药业集团股份有限公司. It contains detailed sections typical of an annual report such as company overview, financial data, management discussion and analysis, accounting policy changes, and comprehensive financial indicators. The document length is 15,000 characters, indicating a full report rather than a brief announcement. It includes audited financial statements and signatures from company officers and auditors, which are characteristic of an official annual report. Therefore, this document fits the definition of an Annual Report (10-K). FY 2024
2025-04-24 Chinese
董事会审计委员会对会计师事务所2024年度履职情况评估及履行监督职责情况的报告
Audit Report / Information Classification · 95% confidence The document is a detailed report from the Board Audit Committee evaluating the performance and supervision of the external audit firm for the fiscal year 2024. It includes information about the audit firm, personnel, audit procedures, and the committee's oversight activities. The content focuses on the audit process and the committee's assessment of the auditor's work, which aligns with the characteristics of an Audit Report / Information filing. The document is not an annual report itself but a specific report on audit oversight and auditor evaluation, fitting the AR category. FY 2024
2025-04-24 Chinese
董事会对独立董事独立性评估的专项意见
Governance Information Classification · 95% confidence The document is a special report on the independence of the company's independent directors, referencing regulatory requirements such as the Shenzhen Stock Exchange listing rules and independent director management measures. It evaluates the independence of current and former independent directors and concludes compliance with relevant regulations. The document is a standalone report focused on governance and regulatory compliance regarding board members' independence, not a full annual report or financial statement. It fits best under Governance Information (CGR) as it details governance practices related to board independence.
2025-04-24 Chinese
关于2025年度日常关联交易预计的公告
Regulatory Filings Classification · 95% confidence The document is an announcement regarding the expected daily related party transactions for the fiscal year 2025 by a company named 葵花药业集团股份有限公司. It details the nature of the related party transactions, the approval process by the board and independent directors, the estimated transaction amounts, and the rationale and impact of these transactions. The document includes no financial statements or detailed financial performance data, but rather focuses on disclosure of related party transactions and their governance. It is not a full annual or interim report, nor an earnings release or audit report. It is a regulatory announcement about related party transactions, which fits best under the category of Regulatory Filings (RNS). The document length is under 5,000 characters and it is a formal announcement, not a report itself.
2025-04-24 Chinese

Browse filings by year

13 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.